Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ERAS |
---|---|---|
09:32 ET | 8722 | 2.29 |
09:34 ET | 200 | 2.29 |
09:36 ET | 387 | 2.305 |
09:39 ET | 200 | 2.31 |
09:41 ET | 2700 | 2.3 |
09:43 ET | 5150 | 2.295 |
09:45 ET | 39760 | 2.265 |
09:48 ET | 882 | 2.25 |
09:50 ET | 600 | 2.25 |
09:52 ET | 400 | 2.235 |
09:54 ET | 800 | 2.245 |
09:56 ET | 100 | 2.245 |
09:57 ET | 8984 | 2.235 |
09:59 ET | 149 | 2.23 |
10:01 ET | 77481 | 2.215 |
10:06 ET | 100 | 2.21 |
10:08 ET | 3665 | 2.2 |
10:10 ET | 1237 | 2.2 |
10:12 ET | 500 | 2.2 |
10:14 ET | 2795 | 2.19 |
10:15 ET | 3076 | 2.205 |
10:17 ET | 4392 | 2.2 |
10:19 ET | 600 | 2.205 |
10:21 ET | 2511 | 2.19 |
10:24 ET | 1700 | 2.19 |
10:26 ET | 4809 | 2.185 |
10:28 ET | 3434 | 2.18 |
10:30 ET | 5140 | 2.18 |
10:32 ET | 3123 | 2.18 |
10:33 ET | 6334 | 2.175 |
10:35 ET | 3400 | 2.175 |
10:37 ET | 7215 | 2.195 |
10:39 ET | 5568 | 2.185 |
10:42 ET | 22987 | 2.205 |
10:44 ET | 700 | 2.2 |
10:46 ET | 740 | 2.2 |
10:48 ET | 3622 | 2.205 |
10:50 ET | 7607 | 2.2 |
10:51 ET | 4532 | 2.21 |
10:53 ET | 400 | 2.21 |
10:55 ET | 1000 | 2.21 |
10:57 ET | 1840 | 2.2105 |
11:00 ET | 900 | 2.21 |
11:02 ET | 900 | 2.215 |
11:04 ET | 4400 | 2.215 |
11:06 ET | 211321 | 2.2 |
11:08 ET | 9309 | 2.2 |
11:09 ET | 68865 | 2.18 |
11:11 ET | 12083 | 2.16 |
11:13 ET | 39024 | 2.175 |
11:15 ET | 1707 | 2.17 |
11:18 ET | 41546 | 2.2 |
11:20 ET | 3000 | 2.2 |
11:22 ET | 7281 | 2.2 |
11:24 ET | 3600 | 2.205 |
11:26 ET | 9782 | 2.215 |
11:27 ET | 600 | 2.215 |
11:29 ET | 2218 | 2.215 |
11:31 ET | 7169 | 2.22 |
11:33 ET | 1600 | 2.22 |
11:36 ET | 10182 | 2.22 |
11:38 ET | 10424 | 2.225 |
11:40 ET | 2432 | 2.225 |
11:42 ET | 3228 | 2.225 |
11:44 ET | 9193 | 2.235 |
11:45 ET | 2400 | 2.235 |
11:47 ET | 7380 | 2.255 |
11:49 ET | 9778 | 2.255 |
11:51 ET | 500 | 2.255 |
11:54 ET | 1700 | 2.25 |
11:56 ET | 1200 | 2.25 |
11:58 ET | 1292 | 2.255 |
12:00 ET | 2600 | 2.26 |
12:02 ET | 900 | 2.26 |
12:03 ET | 900 | 2.26 |
12:05 ET | 1400 | 2.265 |
12:07 ET | 3370 | 2.265 |
12:09 ET | 1136 | 2.265 |
12:12 ET | 1336 | 2.265 |
12:14 ET | 736 | 2.265 |
12:16 ET | 12252 | 2.265 |
12:18 ET | 1400 | 2.265 |
12:20 ET | 11222 | 2.255 |
12:21 ET | 4984 | 2.265 |
12:23 ET | 500 | 2.26 |
12:25 ET | 5788 | 2.25 |
12:27 ET | 24500 | 2.265 |
12:30 ET | 1500 | 2.275 |
12:32 ET | 1000 | 2.275 |
12:34 ET | 16420 | 2.275 |
12:36 ET | 5864 | 2.275 |
12:38 ET | 10875 | 2.265 |
12:39 ET | 2682 | 2.25 |
12:41 ET | 2420 | 2.255 |
12:43 ET | 1200 | 2.25 |
12:45 ET | 1400 | 2.255 |
12:48 ET | 800 | 2.255 |
12:50 ET | 3838 | 2.255 |
12:52 ET | 400 | 2.255 |
12:54 ET | 1236 | 2.25 |
12:56 ET | 700 | 2.25 |
12:57 ET | 600 | 2.25 |
12:59 ET | 1211 | 2.255 |
01:01 ET | 1900 | 2.255 |
01:03 ET | 1151 | 2.255 |
01:06 ET | 1336 | 2.255 |
01:08 ET | 1634 | 2.255 |
01:10 ET | 10636 | 2.255 |
01:12 ET | 1800 | 2.255 |
01:14 ET | 1100 | 2.255 |
01:15 ET | 2400 | 2.255 |
01:17 ET | 989 | 2.25 |
01:19 ET | 1900 | 2.255 |
01:21 ET | 1900 | 2.25 |
01:24 ET | 4900 | 2.255 |
01:26 ET | 5976 | 2.25 |
01:28 ET | 4539 | 2.245 |
01:30 ET | 3564 | 2.245 |
01:32 ET | 21273 | 2.24 |
01:33 ET | 7294 | 2.24 |
01:35 ET | 10116 | 2.245 |
01:37 ET | 11972 | 2.245 |
01:39 ET | 4936 | 2.24 |
01:42 ET | 2680 | 2.24 |
01:44 ET | 2500 | 2.245 |
01:46 ET | 4942 | 2.25 |
01:48 ET | 13373 | 2.265 |
01:50 ET | 15793 | 2.27 |
01:51 ET | 2420 | 2.275 |
01:53 ET | 3250 | 2.275 |
01:55 ET | 30039 | 2.285 |
01:57 ET | 3764 | 2.29 |
02:00 ET | 13629 | 2.295 |
02:02 ET | 42480 | 2.295 |
02:04 ET | 5087 | 2.27 |
02:06 ET | 3400 | 2.275 |
02:08 ET | 4057 | 2.29 |
02:09 ET | 5559 | 2.295 |
02:11 ET | 2500 | 2.3 |
02:13 ET | 1800 | 2.295 |
02:15 ET | 2300 | 2.295 |
02:18 ET | 38060 | 2.3 |
02:20 ET | 5550 | 2.3 |
02:22 ET | 11181 | 2.3 |
02:24 ET | 24545 | 2.285 |
02:26 ET | 2100 | 2.295 |
02:27 ET | 17917 | 2.295 |
02:29 ET | 32923 | 2.3 |
02:31 ET | 7588 | 2.3 |
02:33 ET | 16635 | 2.3 |
02:36 ET | 18926 | 2.3 |
02:38 ET | 15648 | 2.3 |
02:40 ET | 14602 | 2.305 |
02:42 ET | 23309 | 2.33 |
02:44 ET | 2800 | 2.325 |
02:45 ET | 6889 | 2.335 |
02:47 ET | 7322 | 2.35 |
02:49 ET | 2831 | 2.35 |
02:51 ET | 11735 | 2.365 |
02:54 ET | 1500 | 2.365 |
02:56 ET | 55712 | 2.375 |
02:58 ET | 1500 | 2.375 |
03:00 ET | 5100 | 2.375 |
03:02 ET | 22337 | 2.355 |
03:03 ET | 2341 | 2.35 |
03:05 ET | 11374 | 2.35 |
03:07 ET | 2600 | 2.35 |
03:09 ET | 2423 | 2.35 |
03:12 ET | 3700 | 2.35 |
03:14 ET | 4000 | 2.355 |
03:16 ET | 14758 | 2.365 |
03:18 ET | 41193 | 2.355 |
03:20 ET | 7625 | 2.34 |
03:21 ET | 3127 | 2.34 |
03:23 ET | 27778 | 2.335 |
03:25 ET | 13005 | 2.345 |
03:27 ET | 25000 | 2.355 |
03:30 ET | 22960 | 2.345 |
03:32 ET | 2600 | 2.34 |
03:34 ET | 5200 | 2.345 |
03:36 ET | 18057 | 2.34 |
03:38 ET | 16576 | 2.345 |
03:39 ET | 5402 | 2.34 |
03:41 ET | 9200 | 2.345 |
03:43 ET | 17241 | 2.36 |
03:45 ET | 25874 | 2.365 |
03:48 ET | 33606 | 2.375 |
03:50 ET | 50275 | 2.355 |
03:52 ET | 13288 | 2.365 |
03:54 ET | 41935 | 2.375 |
03:56 ET | 90381 | 2.35 |
03:57 ET | 82179 | 2.365 |
03:59 ET | 3864947 | 2.36 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Erasca Inc | 561.6M | -2.8x | --- |
Savara Inc | 556.9M | -10.5x | --- |
Humacyte Inc | 571.6M | -4.8x | --- |
Celcuity Inc | 575.0M | -5.9x | --- |
Mineralys Therapeutics Inc | 580.9M | -5.4x | --- |
Third Harmonic Bio Inc | 532.3M | -17.4x | --- |
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $561.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 238.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.84 |
Book Value | $2.10 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.